Daniel Leightley

Nov 28, 2024 | rusi.org | Stuart Middleton |Daniel Leightley |Patrick Hinton |Sarah Ashbridge |Daniel Adler |Maria Liakata | +1 more

RUSI JournalVOLUME 169ISSUE 6Stuart E Middleton, Daniel Leightley, Major Patrick Hinton, Dr Sarah Ashbridge, Daniel A Adler, Alec Banks, Maria Liakata, Brant Chee and Ana BasiriLong ReadAI is being used to enhance research and practice in military mental health. AI is a cross-cutting technology that is having a major impact on behavioural analysis in both the defence and mental health domains. Employing AI well may boost the readiness and resilience of military personnel.

Oct 18, 2024 | kcl.ac.uk | Daniel Leightley |Nicholas Cummins

Earlier this week, academics came together with charity leaders, industry members and civil servants for an event at King’s College London that explored opportunities for the use of artificial intelligence (AI) in the Armed Forces sector. Organised by the Department of Population Health Sciences at King’s in partnership with Combat Stress and funded by the Forces in Mind Trust, the event aimed to build a consensus within the Armed Forces charitable sector on the use of AI.

May 22, 2024 | kcl.ac.uk | Rina Dutta |Ben Carter |Daniel Leightley

New research from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London, in partnership with YoungMinds – the UK’s leading children’s mental health charity - has found high levels of problematic mobile phone use, disturbed sleep, and self-harm among young people with mental health conditions.

Feb 9, 2024 | nationalelfservice.net | Grace Williamson |Daniel Leightley

The United States has a complex relationship with cannabis and its legal status, notably a high level of tension between state and federal level (Young-Wolff et al., 2022). At the federal level, cannabis remains classified as a controlled substance under the Controlled Substances Act (1906). This means it is officially regarded as having a high potential for abuse and isn’t a recognised medical treatment option for any disease or condition by the United States Food and Drug Administration.